沙利度胺联合VAD方案治疗多发性骨髓瘤的临床疗效观察

Clinical observation of therapeutic effect of thalidomide combined with VAD chemotherapy on multiple myeloma

目的探讨沙利度胺联合VAD方案治疗多发性骨髓瘤的临床疗效和不良反应。方法将36例入本院初治的多发性骨髓瘤患者随机分为治疗组(n=19)和对照组(n=17),两组患者均接受VAD方案化疗,治疗组化疗同时给予沙利度胺口服治疗,疗程均为3～4个月,观察两组患者治疗有效率及不良反应的发生情况。结果治疗组的治疗有效率显著高于对照组(P<0.05);两组的不良反应有皮疹、脱发、恶心呕吐、肺部感染、骨髓抑制、便秘、一过性高血糖等,但患者均可耐受。结论沙利度胺联合VAD方案治疗多发性骨髓瘤的疗效优于单用VAD方案,疾病控制率高,可优先应用于治疗多发性骨髓瘤。

Objective To investigate the clinical effect and adverse effects of thalidomide combined with VAD chemotherapy on multiple myeloma.Method 36 untreated patients with multiple myeloma were randomly divided into treatment group（n=19） and control group（n=17）.All the patients received VAD chemotherapy.Patients in treatment group also received oral dose of thalidomide at the same time for 3～4 months.The effective rate and adverse effects were observed and compared between the two groups.Results The effective rate in treatment group was significantly higher than the control group（P〈0.05）.The adverse effects in both groups were skin rash,alopecia,nausea and vomiting,pulmonary infection,myelosuppression,constipation,transient hyperglycemia,etc,but all the adverse effects were endurable.Conclusion Thalidomide combined with VAD chemotherapy was more effective and was able to be preferentially applied on the treatment of multiple myeloma.